Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18751502 | Immunogenic Compounds For Cancer Therapy | June 2024 | August 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18732517 | Reducing side effects of immunotherapy using genetically modified hematopoietic cells | June 2024 | February 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18674099 | METHODS OF ASSESSING OR MONITORING A RESPONSE TO A CELL THERAPY | May 2024 | October 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18658421 | OX40-Binding Polypeptides and Uses Thereof | May 2024 | February 2025 | Allow | 9 | 0 | 0 | No | No |
| 18658403 | REPLICATION-DEFICIENT ARENAVIRUS PARTICLES AND TRI-SEGMENTED ARENAVIRUS PARTICLES AS CANCER VACCINES | May 2024 | November 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18605049 | MRNA THERAPEUTIC COMPOSITIONS | March 2024 | August 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18589536 | PD-1 Single Domain Antibodies and Therapeutic Compositions Thereof | February 2024 | January 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18429213 | Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens | January 2024 | June 2025 | Allow | 16 | 0 | 0 | Yes | No |
| 18418078 | Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen | January 2024 | December 2024 | Allow | 11 | 1 | 1 | No | No |
| 18505881 | MRNA THERAPEUTIC COMPOSITIONS | November 2023 | February 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18288268 | ANTI-CNTN4-SPECIFIC ANTIBODIES AND USE THEREOF | October 2023 | March 2026 | Allow | 29 | 0 | 0 | Yes | No |
| 18486678 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | October 2023 | April 2025 | Abandon | 18 | 0 | 2 | No | No |
| 18485163 | ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE | October 2023 | June 2024 | Allow | 8 | 0 | 0 | No | No |
| 18473002 | ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | September 2023 | September 2024 | Allow | 12 | 1 | 0 | No | No |
| 18457778 | DIAGNOSTIC OR PREDICTOR OF RELAPSING REMITTING MULTIPLE SCLEROSIS | August 2023 | November 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18364644 | THERAPEUTIC AGENT TARGETED TO RECEPTOR PROTEIN, TEST AGENT, ANTIBODY THAT BINDS TO RECEPTOR PROTEIN, AND SCREENING METHOD FOR MOLECULARLY TARGETED DRUGS | August 2023 | June 2024 | Allow | 10 | 1 | 0 | No | No |
| 18363672 | T CELL RECEPTORS | August 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18275169 | Materials and Methods for Monitoring Cancer by Administering an Anti-MCL1 Antibody | July 2023 | March 2026 | Allow | 31 | 0 | 0 | Yes | No |
| 18354395 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) | July 2023 | April 2025 | Abandon | 21 | 2 | 1 | No | No |
| 18348384 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses | July 2023 | August 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18340242 | SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE SAME, AND USES THEREOF | June 2023 | December 2024 | Allow | 18 | 2 | 1 | No | No |
| 18339663 | T CELL RECEPTORS | June 2023 | August 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18324915 | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity | May 2023 | September 2024 | Allow | 16 | 2 | 1 | No | No |
| 18318610 | BISPECIFIC ANTIBODY | May 2023 | December 2023 | Allow | 7 | 1 | 1 | Yes | No |
| 18310120 | METHODS, KITS, AND COMPOSITIONS FOR ENHANCING CELLULAR THERAPY | May 2023 | January 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18194105 | Anti-Coronavirus Antibodies and Methods of Use | March 2023 | August 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18186730 | Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form | March 2023 | September 2023 | Allow | 6 | 0 | 1 | Yes | No |
| 18172773 | ANTI-P53 ANTIBODIES | February 2023 | August 2024 | Allow | 18 | 2 | 0 | No | No |
| 18157632 | TCR AND PEPTIDES | January 2023 | August 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18151112 | DYSFUNCTIONAL ANTIGEN-SPECIFIC CD8+ T CELLS IN THE TUMOR MICROENVIRONMENT | January 2023 | October 2024 | Abandon | 22 | 1 | 1 | No | No |
| 18081760 | Therapeutic Substances, their Preparation and Diagnostic Procedure | December 2022 | June 2024 | Abandon | 18 | 0 | 1 | No | No |
| 17984814 | METHODS FOR TREATING AUTOIMMUNE DISEASES | November 2022 | December 2025 | Abandon | 37 | 5 | 0 | Yes | Yes |
| 18048614 | MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELL RELATED CANCER CELLS AND USES THEREOF | October 2022 | March 2026 | Allow | 41 | 1 | 1 | No | No |
| 18047432 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | October 2022 | July 2024 | Allow | 20 | 3 | 1 | Yes | No |
| 18045802 | ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE | October 2022 | February 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17918000 | USE OF VIRAL VECTORS FOR CORONAVIRUS VACCINE PRODUCTION | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17932450 | THERAPEUTIC AGENT TARGETED TO RECEPTOR PROTEIN, TEST AGENT, ANTIBODY THAT BINDS TO RECEPTOR PROTEIN, AND SCREENING METHOD FOR MOLECULARLY TARGETED DRUGS | September 2022 | June 2024 | Allow | 21 | 1 | 1 | No | No |
| 17931395 | CLD PROTEIN MUTANT AND APPLICATION THEREOF | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17930867 | Treatment of Multiple Sclerosis with Anti-CD52 Antibodies | September 2022 | January 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17929063 | IMMUNOGENIC COMPOUNDS FOR CANCER THERAPY | September 2022 | April 2024 | Allow | 19 | 1 | 1 | No | No |
| 17908299 | NUCLEIC ACID CONSTRUCT, RECOMBINANT INFLUENZA VIRUS, METHOD FOR PREPARING A RECOMBINANT INFLUENZA VIRUS, COMPOSITION AND USE | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17802500 | TRIAGING METHOD USING CELL FREE NUCLEOSOME LEVELS | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17801797 | METHOD FOR IMPROVING ANTIGEN IMMUNOGENICITY, CORONAVIRUS ANTIGEN, USE THEREOF, RECOMBINANT VECTOR, EXPRESSION KIT, TRANSGENIC CELL LINE, RECOMBINANT BACTERIUM, CORONAVIRUS VACCINE, PREPARATION METHOD OF ANTIGEN AND NUCLEOTIDE SEQUENCE | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17820803 | METHODS FOR DETECTING MULTIPLE SCLEROSIS (MS) DIAGNOSTIC AUTOANTIBODIES | August 2022 | August 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17820529 | T CELL RECEPTORS | August 2022 | December 2022 | Allow | 4 | 1 | 0 | No | No |
| 17820554 | GROUP A STREP IMMUNOGENIC COMPOSITIONS WITH POLYSACCHARIDE-PROTEIN CONJUGATES | August 2022 | January 2026 | Allow | 41 | 1 | 1 | Yes | No |
| 17799648 | BISPECIFIC ANTIBODY | August 2022 | February 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17904157 | ENGINEERED INFLUENZA NEURAMINIDASE ANTIGENS | August 2022 | January 2026 | Allow | 41 | 1 | 1 | No | No |
| 17819401 | COMBINATION THERAPY TO TREAT BRAIN CANCER | August 2022 | March 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17818106 | OX40-Binding Polypeptides and Uses Thereof | August 2022 | February 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17797784 | SARS-COV-2 MRNA DOMAIN VACCINES | August 2022 | March 2026 | Allow | 43 | 2 | 0 | Yes | No |
| 17760290 | METHOD OF TREATING A SOLID TUMOR WITH A COMBINATION OF AN IL-7 PROTEIN AND CAR-BEARING IMMUNE CELLS | August 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17816550 | IMMUNOTOXINS, FORMULATIONS THEREOF AND THEIR USE IN MEDICINE | August 2022 | April 2025 | Allow | 32 | 1 | 1 | No | No |
| 17793952 | PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME) T CELL RECEPTORS AND METHODS OF USE THEREOF | July 2022 | December 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17812592 | Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer | July 2022 | June 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17812264 | Chimeric Antigen Receptor-Modified NK-92 Cells | July 2022 | April 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17791685 | COMPOSITION COMPRISING ANTIGEN-PRESENTING CELL CO-EXPRESSING MHC AND TUMOR ANTIGEN, AND CANCER TREATMENT USING SAME | July 2022 | February 2026 | Allow | 43 | 1 | 1 | No | No |
| 17807473 | BCMA-BINDING ANTIBODIES AND USES THEREOF | June 2022 | March 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17843616 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | June 2022 | July 2024 | Allow | 25 | 1 | 1 | No | No |
| 17824482 | ANTIBODY COMPOSITIONS | May 2022 | February 2024 | Allow | 21 | 1 | 0 | No | No |
| 17779989 | ANTI-PHENACETIN MONOCLONAL ANTIBODY HYBRIDOMA CELL STRAIN AD AND ITS PREPARATION METHOD AND APPLICATION | May 2022 | September 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17611357 | Method for Predicting Therapeutic Response to Serine-Theronine Kinase Braf Inhibitor Drugs | May 2022 | December 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17746645 | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY | May 2022 | December 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17740100 | ANTI-SIGLEC-5 ANTIBODIES AND METHODS OF USE THEREOF | May 2022 | January 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 17720903 | ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER | April 2022 | February 2026 | Abandon | 46 | 4 | 1 | No | No |
| 17694890 | ANTI-CD40 ANTIBODIES AND USES THEREOF | March 2022 | December 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17640283 | METHODS FOR DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER | March 2022 | August 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17650025 | MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | February 2022 | January 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17650018 | MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | February 2022 | January 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17591231 | ANTI-SIRP ALPHA ANTIBODIES | February 2022 | March 2023 | Allow | 14 | 0 | 1 | Yes | No |
| 17631416 | HANTAVIRUS ANTIGENIC COMPOSITION | January 2022 | January 2026 | Allow | 47 | 1 | 1 | No | No |
| 17574152 | T CELL RECEPTORS | January 2022 | April 2024 | Allow | 27 | 2 | 1 | No | No |
| 17623867 | METHODS AND COMPOSITIONS FOR TREATMENT OF PANCREATIC CANCER | December 2021 | December 2025 | Allow | 47 | 1 | 1 | No | No |
| 17621689 | SIRPalpha-SILENCED NATURAL KILLER (NK) CELLS | December 2021 | April 2025 | Allow | 40 | 0 | 0 | Yes | No |
| 17557647 | BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING ANTI-FAP CLONE 212 | December 2021 | August 2024 | Allow | 32 | 2 | 1 | No | No |
| 17549442 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEIN | December 2021 | September 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17616050 | A CHEMOENZYMATIC METHOD FOR THE DETECTION OF CELL-CELL PROXIMITY INTERACTION AND ISOLATION OF TUMOR-SPECIFIC ANTIGEN REACTIVE T CELLS FOR IMMUNE THERAPY | December 2021 | March 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17528103 | PAR1 MODULATION TO ALTER MYELINATION | November 2021 | August 2023 | Allow | 20 | 1 | 0 | No | No |
| 17524016 | PD-1 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF | November 2021 | December 2023 | Allow | 25 | 1 | 1 | No | No |
| 17608079 | T CELL GENE EXPRESSION ANALYSIS FOR USE IN T CELL THERAPIES | November 2021 | January 2026 | Allow | 51 | 2 | 1 | Yes | No |
| 17607141 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAUOPATHY | October 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17512257 | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) | October 2021 | March 2023 | Allow | 17 | 0 | 0 | No | No |
| 17606412 | ENGINEERED NATURAL KILLER CELLS REDIRECTED TOWARD PURINERGIC SIGNALING, CONSTRUCTS THEREOF, AND METHODS FOR USING THE SAME | October 2021 | February 2026 | Allow | 52 | 2 | 1 | Yes | No |
| 17501122 | T CELL RECEPTORS | October 2021 | March 2023 | Allow | 17 | 1 | 0 | No | No |
| 17501200 | T CELL RECEPTORS | October 2021 | April 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17490600 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17489249 | Antigenic Multimeric Respiratory Syncytial Virus Polypeptides | September 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17475975 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses | September 2021 | October 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17472461 | IMMUNOTHERAPY METHOD COMPRISING ADMINISTERING A COMBINATION OF IMMUNE EFFECTOR CELLS AND NON-TARGET HEMATOPOIETIC CELLS | September 2021 | June 2022 | Allow | 9 | 1 | 1 | No | No |
| 17396033 | TUMOR CELL VACCINES | August 2021 | February 2022 | Allow | 6 | 0 | 1 | Yes | No |
| 17428784 | Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes | August 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17394972 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | August 2021 | April 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17427329 | METHOD OF PREDICTING SURVIVAL RATES FOR CANCER PATIENTS | July 2021 | July 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17426646 | PROSPECTIVE MARKERS IN TRAUMATIC BRAIN INJURY (TBI) | July 2021 | January 2026 | Allow | 53 | 5 | 1 | Yes | No |
| 17383043 | Reducing Immune Inhibition Induced by SIGLEC-15 | July 2021 | July 2023 | Allow | 24 | 1 | 1 | No | No |
| 17421365 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1) | July 2021 | May 2024 | Allow | 35 | 0 | 0 | No | No |
| 17360437 | MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 | June 2021 | November 2023 | Allow | 29 | 3 | 0 | No | No |
| 17360438 | MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 | June 2021 | February 2024 | Allow | 32 | 2 | 1 | Yes | Yes |
| 17419203 | CLAUDIN18.2 BINDING MOIETIES AND USES THEREOF | June 2021 | December 2024 | Allow | 42 | 1 | 1 | No | No |
| 17417896 | TYPE 1 INTERFERON NEUTRALIZING FC-FUSION PROTEIN AND USE THEREOF | June 2021 | May 2025 | Allow | 47 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JOHANSEN, PETER N..
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JOHANSEN, PETER N. works in Art Unit 1644 and has examined 174 patent applications in our dataset. With an allowance rate of 51.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner JOHANSEN, PETER N.'s allowance rate of 51.7% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JOHANSEN, PETER N. receive 2.54 office actions before reaching final disposition. This places the examiner in the 74% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JOHANSEN, PETER N. is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +31.6% benefit to allowance rate for applications examined by JOHANSEN, PETER N.. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.0% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 19.2% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 35% percentile among all examiners. Of these withdrawals, 44.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 64.3% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.2% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.